Nanalysis Scientific Corp.
NSCIF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.10 | -0.05 | -0.03 | 1.17 |
| FCF Yield | 4.11% | -43.22% | -24.51% | -4.98% |
| EV / EBITDA | -6.68 | -6.52 | -13.44 | 58.10 |
| Quality | ||||
| ROIC | -9.87% | -24.97% | -15.53% | -3.80% |
| Gross Margin | 28.02% | 13.95% | 42.18% | 63.83% |
| Cash Conversion Ratio | -0.24 | 0.67 | 0.94 | 0.68 |
| Growth | ||||
| Revenue 3-Year CAGR | 22.38% | 21.06% | 46.62% | 24.25% |
| Free Cash Flow Growth | 108.91% | -1.42% | -270.12% | -19.27% |
| Safety | ||||
| Net Debt / EBITDA | -2.22 | -2.40 | -1.37 | -3.21 |
| Interest Coverage | -2.56 | -40.92 | -65.20 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 7.47 | 4.23 | 1.94 | 1.58 |
| Cash Conversion Cycle | 72.73 | 135.74 | 146.37 | 90.85 |